Origami Therapeutics, Inc.
Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified sm
Y Combinator
yc-company-directory #4782Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified sm
sourceOrigami Therapeutics, Inc. is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Origami Therapeutics, Inc.
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
1910
match 92We are the only AI-native biotech pioneering small and large molecule therapeutics discovery by integrating massive multimodal data, frontier AI models, and high-throughput lab automation into an infrastructure for AI-enabled drug discovery.
shared extracted concept terms: model, drug, discovery; shared product terms: biotech, small, molecule, therapeutic; shared product theme: health and clinical care; shared affiliation: Y Combinator
Harmonic Discovery
match 82We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing
shared extracted concept terms: drug, discovery; shared product terms: drug, discovery, develop, therapeutic; shared product theme: health and clinical care; shared affiliation: Y Combinator
Parallel Bio
match 76Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of nov
shared extracted concept terms: drug, human, disease; shared product terms: disease, drug, discovery, human; shared product theme: health and clinical care; shared affiliation: Y Combinator
Nanograb
match 72Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.
shared extracted concept terms: drug, discovery; shared product terms: drug, discovery, novel, small; same category: AI infrastructure; shared affiliation: Y Combinator
CellType
match 69CellType is building an agentic drug company. AI agents that run the full drug discovery pipeline on top of biological foundation models that simulate human biology. Our core technology, developed with Google DeepMind, has already discovered and validated a new cancer treatment signal. We’re working with Top 10 pharma.
shared extracted concept terms: human, model; shared product terms: drug, discovery, model, human; shared affiliation: Y Combinator
ParcelBio
match 64ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.
shared extracted concept terms: disease; shared product terms: therapeutic, novel, protein, disease; shared product theme: health and clinical care; shared affiliation: Y Combinator